Amryt Pharma Share Discussion Threads

[papillon] 15/4/2021 22:11

radar Posts: 3,341 Price: 205.00 No Opinion Someone Today 11:56 Bought 110,000 shares yesterday, usual pattern, lift is coming >>>>>>>>>>>>>>>>>>>>>>>>> And someone sold 225,000 shares valued at £450,000 earlier today (reporting delayed because of the size of the trade).

[bermudashorts] 12/4/2021 10:07

yep both of these events have been announced via RNS - see below Https://www.investegate.co.uk/amryt-pharma-plc--amyt-/gnw/amryt-announces-validation-of-its-maa-by-the-ema-for-oleogel-s10---160--filsuvez--174--/20210329070000H4877/ Https://www.investegate.co.uk/amryt-pharma-plc--amyt-/gnw/amryt-submits-a-new-drug-application-to-the-us-food-and-drug-administration-for-oleogel-s10---filsuvez--174--/20210331070000H5647/

[diamondstar1] 12/4/2021 08:42

According to Epidermolysis Bullosa News - article on 9th April 2021 by Steve Bryson - Amryt has now completed FDA rolling submission for Filsuvez. In addition, Amryt’s filing for EU Marketing Authorisation has also been accepted by EMEA. All going in the right direction for Amryt.

[papillon] 07/4/2021 13:10

The following was posted today by, Bronxville, on the lse AMYT bb. Many thanks Bronxville. Cannacord Genuity $40 targetToday 11:12 Amryt Pharma (AMYT) Received its Third Buy in a Row By Ryan Adsit Amryt Pharma (AMYT) Received its Third Buy in a Row After Leerink Partners and Maxim Group gave Amryt Pharma (NASDAQ: AMYT) a Buy rating last month, the company received another Buy, this time from Canaccord Genuity. Analyst Michelle Gilson maintained a Buy rating on Amryt Pharma yesterday and set a price target of $40.00. The company’s shares closed last Monday at $14.29. According to TipRanks.com, Gilson is a 4-star analyst with an average return of 25.2% and a 51.4% success rate. Gilson covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Sigilon Therapeutics, and Travere Therapeutics. Currently, the analyst consensus on Amryt Pharma is a Strong Buy with an average price target of $33.50, a 136.7% upside from current levels. In a report issued on March 31, Maxim Group also initiated coverage with a Buy rating on the stock with a $27.00 price target hTTps://www.analystratings.com/articles/amryt-pharma-amyt-received-its-third-buy-in-a-row/

[papillon] 07/4/2021 12:22

U.k. Spac is the name and SPC is it's epic code. I gave all the details in my post!!!! Here's the advfn bb for the company. https://uk.advfn.com/cmn/fbb/thread.php3?id=48077919 The company was formerly called Mountfield Group.

[dingodollars] 07/4/2021 11:12

What's the name of the SPAC / SPV he's interested in?

[papillon] 07/4/2021 08:34

I see Cathal Friel has an interest in another shell called U. k. Spac (SPC). Probably hoping to replicate his success with ORPH, which was originally a shell he very successfully invested in. I wonder if Bronxville is invested in SPAC? He's done very well with ORPH.

[papillon] 07/4/2021 07:26

Blimey, no RNS this morning! 😂 Can on chaps you can do better than this! 😂

[papillon] 06/4/2021 12:56

I noticed there was a trade for one solitary share went through @ close to 10am @ 200p. Any significance I wonder, or a mistake? Some believe the solitary share trade is a signal between MM's that significant news is imminent, but who knows?

[papillon] 06/4/2021 12:38

You can buy below the mid price of the official spread. A couple of circa £20k buys went through @ 204p, but a circa £40k sell @ 200p followed.

[bugsbunny10] 06/4/2021 10:49

Nice buys going through today. Moving up this week.

[papillon] 06/4/2021 07:49

Another day, yet another RNS! 😁 This news could go down well on Nasdaq this afternoon.

[whatno] 05/4/2021 10:26

@SIDAM - thanks for your feedback on the generic issue. Rory shared a paper on the challenges around marketing generics for orphan indications and your points echo what was said. This has changed my view of Amryt somewhat. I had seen (especially) Lomitapide and Metreleptin as sunset products that, once IP protection expired, would fall by the wayside. However, that seems much less likely given the relatively small revenue and specialized distribution requirements. Of course, there are other factors that could still impact revenues, approval of a better drug or price controls are two possibilities. However, I now see the revenues as more like an annuity income that is robust (even during COVID) and there for the foreseeable future. As Joe Wiley has pointed out before, this will fund Amryt's development of newer products going forward without bleeding existing shareholders through dilution. This is pretty rare for companies developing products in the biotech/pharma space.

[punter6] 05/4/2021 08:38

Personally I don't understand this Bitcoin craze. In fact,I don't understand Bitcoin at all!

[papillon] 04/4/2021 11:46

O/T. There is a potentially bullish Inverse Head & Shoulders (IH&S) forming on the Bitcoin chart. Possible target price is 65k+. PS You can't predict an IH&S, or any other chart pattern for that matter. You have to wait for it to form. It has a 70% chance of successful outcome IF it forms. There was a successful IH&S formed during mid February to early March. I don't own any Bitcoin. I suspect it's madness and the price will start to crash one day, but when and from what peak I have no idea. free stock charts from uk.advfn.com

[papillon] 01/4/2021 17:40

"Wot, no RNS today?" 🤣🤣 No wonder the share price went down! 😂😂 What were the AMYT management thinking of? 🤣

[alphabravo321] 31/3/2021 07:56

Dear Joe, what are you going to do with the $40 mill

[moorsie2] 31/3/2021 07:54

Busy end to Q1!

[richpassi] 31/3/2021 07:10

RNS Hat trick :)

[spuddymadrid] 30/3/2021 14:42

hxxps://www.clinicaltrialsarena.com/comment/amryts-oleogel-s10-approvable-in-epidermolysis-bullosa/ Looks reasonably good

[sidam] 30/3/2021 10:34

I have previously questioned the company on generic competition. They pointed out that to date there has been no generic entry into the orphan drug market. The reason they gave was that the markets were different. With normal drugs the route to market is simple. There are national distributors and virtually all pharmacies will carry competing products. With orphan drugs, the sale process is often virtually a consultancy. There are limited doctors and the use of the drug can be combined with dietary advice etc. In some cases, each pharmacy has to be licensed to stock the product. Generic companies are just not set up to offer that. Although the price is high, total revenues may not be large enough to warrant setting up specialised distribution and sales forces.

[whatno] 30/3/2021 09:22

It will be interesting to see if Amryt can use further indications as a means of defence against generics entering the market. It's hard to see how it would be commercially viable to develop Lomitapide for FCS based on the existing dates for patent expiry. Maybe we'll get an update when they agree on a path forward with the regulators.

[moorsie2] 30/3/2021 07:59

Another day - another announcement